SCHEMBL676142

SCHEMBL676142

c1cncc(Oc2cccnc2)c1

nearest known ligand 0.82

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.82
TDP1 Q9NUW8 1/20 0.82
CYP19A1 P11511 3/20 0.64
CYP11B1 P15538 1/20 0.60
CYP11B2 P19099 1/20 0.60
HTT P42858 1/20 0.58
ALDH1A1 P00352 3/20 0.57
SMN1; SMN2 Q16637 1/20 0.57
LTA4H P09960 3/20 0.56
CHRNB2 P17787 3/20 0.50
CHRNA4 P43681 3/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2A6 P11509 1/20 0.50
MAP4K4 O95819 1/20 0.47
FFAR4 Q5NUL3 1/20 0.46
KDM4C Q9H3R0 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30535283 1.00 LMNA (0.82) LMNATDP1CYP19A1CYP11B1CYP11B2
Potassium SCHEMBL6776357 0.97 LMNA (0.78) LMNATDP1CYP19A1CYP11B1CYP11B2
SCHEMBL16114401 0.95 LMNA (0.75) LMNATDP1CYP19A1CYP11B1CYP11B2
SCHEMBL78141 0.93 LMNA (0.72) LMNATDP1CYP19A1CYP11B1CYP11B2
SCHEMBL29500180 0.93 LMNA (0.72) LMNATDP1CYP19A1CYP11B1CYP11B2
SCHEMBL22061921 0.93 LMNA (0.87) LMNATDP1CYP19A1CYP11B1CYP11B2
Bromide SCHEMBL9391382 0.91 LMNA (0.69) LMNATDP1CYP19A1CYP11B1CYP11B2
SCHEMBL27968872 0.91 LMNA (0.69) LMNATDP1CYP19A1CYP11B1CYP11B2
Hydrochloric Acid SCHEMBL9386460 0.91 LMNA (0.69) LMNATDP1CYP19A1CYP11B1CYP11B2
SCHEMBL11107948 0.85 LMNA (0.62) LMNATDP1CYP19A1CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111303150-A High-efficiency narrow-half-peak-width aggregation state luminescent material 苏州大学 2020-06-19 CN claimed
US-20090253728-A1 Methods and Compositions for Treating Nociceptive Pain MEYERSON LAURENCE R 2009-10-08 US claimed
EP-1789028-A2 COMPOSITIONS FOR TREATING NOCICEPTIVE PAIN Neuromolecular Pharmaceuticals Inc (US) 2007-05-30 EP claimed
US-20060052370-A1 Methods and compositions for treating nociceptive pain NEUROMOLECULAR, INC. 2006-03-09 US claimed
WO-2006024018-A2 COMPOSITIONS FOR TREATING NOCICEPTIVE PAIN NEUROMOLECULAR PHARMACEUTICALS, INC. (US) 2006-03-02 WO claimed
US-4874775-A INHIBIT PHYTOPATHOGENS ELI LILLY AND COMPANY (US) 1989-10-17 US claimed
EP-3200801-B1 METHODS OF TREATING PANCREATIC CANCER UNIV MARYLAND (US) 2024-04-24 EP disclosed
US-11707468-B2 Methods of treating pancreatic cancer UNIVERSITY OF MARYLAND, BALTIMORE (US) 2023-07-25 US disclosed
EP-3921324-A1 INHIBITORS OF ADENYLATE-FORMING ENZYME MENE Memorial Sloan Kettering Cancer Center (US) 2021-12-15 EP disclosed
WO-2021107590-A1 NOVEL TRIAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME 주식회사 대웅제약 2021-06-03 WO disclosed
US-20200261475-A1 METHODS OF TREATING PANCREATIC CANCER UNIVERSITY OF MARYLAND, BALTIMORE (US) 2020-08-20 US disclosed
WO-2020163673-A1 INHIBITORS OF ADENYLATE-FORMING ENZYME MENE MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2020-08-13 WO disclosed
US-10675289-B2 Methods of treating pancreatic cancer UNIVERSITY OF MARYLAND, BALTIMORE (US) 2020-06-09 US disclosed
US-4874775-A INHIBIT PHYTOPATHOGENS ELI LILLY AND COMPANY (US) 1989-10-17 US disclosed
US-4698091-A 2-phenylpyrimidines, 2-naphthylpyrimidines and 2-heterocyclylpyrimidines as safeners for protecting cultivated plant against phytotoxic damage caused by herbicides CIBA-GEIGY CORPORATION (US) 1987-10-06 US disclosed
EP-0206581-A2 Agriculturally-useful sulfonamides ELI LILLY AND COMPANY (US) 1986-12-30 EP disclosed
CN-86103621-A The method of the sulphonamide of preparation agriculturally useful 1986-12-10 CN disclosed
EP-0148826-A1 FUNGICIDAL, HERBICIDAL AND PLANT GROWTH REGULATING PYRIDYL-CONTAINING ETHERS CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) 1985-07-24 EP disclosed
WO-1985000289-A1 FUNGICIDAL, HERBICIDAL AND PLANT GROWTH REGULATING PYRIDYL-CONTAINING ETHERS CHEVRON RESEARCH COMPANY (US) 1985-01-31 WO disclosed
US-4407806-A PRE- AND POSTEMERGENCE HERBICIDES CHEVRON RESEARCH COMPANY (US) 1983-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10675289-B2 Methods of treating pancreatic cancer RNASE1, PNLIP, AMY2A LMNA 2274/4885TDP1 3214/4885CYP19A1 3488/4885
US-11707468-B2 Methods of treating pancreatic cancer RNASE1, PNLIP, AMY2A LMNA 2274/4885TDP1 3214/4885CYP19A1 3488/4885
US-20200261475-A1 METHODS OF TREATING PANCREATIC CANCER RNASE1, PNLIP, AMY2A LMNA 2274/4885TDP1 3214/4885CYP19A1 3488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.